Siludi Pharmaceutical Co., Ltd. (01244): Enveda's conditional approval to regular approval supplementary application approved by the State Drug Administration

Zhitongcaijing · 1d ago

Zhitong Finance App News, Siludi Pharmaceutical Co., Ltd. (01244) issued an announcement. Envida ® (generic name: envolizumab injection) was officially approved by the National Drug Administration (NMPA) on November 17, 2026, and was officially approved by the National Drug Administration (NMPA) on November 17, 2026, with approval notice number 2026B08210.

Envida ® (generic name: Envolimab injection, original research code: KN035) is a recombinant humanized anti-programmed death ligand 1 (PD-L1) single-domain antibody Fc fusion protein. Enveda ® is independently developed by Corning Jerry Biopharmaceuticals (Corning Jerry, an exempted limited company incorporated in accordance with Cayman Islands law on March 28, 2018 and listed on the Stock Exchange (stock code: 9966) and its subsidiaries (all independent third parties)), and has been developed in cooperation with the Company since 2016. On March 30, 2020, Jiangsu Corning Jerry Biopharmaceutical Co., Ltd. (Jiangsu Corning Jerry, a wholly-owned subsidiary of Corning Jerry), Siludi Pharmaceutical Co., Ltd. (Jiangsu Xiansheng, a subsidiary of Xiansheng Pharmaceutical Group Co., Ltd., whose shares are listed on the Stock Exchange (stock code: 2096)) entered into a cooperation agreement. Under the agreement, Jiangsu Xiansheng was granted exclusive marketing rights for Enveda® for oncology indications in mainland China and priority transfer rights under external licensing or transfer. In January 2024, the Company entered into a licensing agreement with Corning Jerry and Glenmark Specialty S.A. (Glenmark), whereby Thiludi Pharmaceuticals and Corning Jerry agreed to grant Glenmark an exclusive license and sub-license for Enveda® oncology indications (including) to develop and commercialize Enveda in all areas of oncology use (including) in India, Asia Pacific (excluding Singapore, Thailand and Malaysia), the Middle East and Africa, Russia, the CIS countries and Latin America ®. Furthermore, as the world's first subcutaneous PD-L1 inhibitor, it was approved by the National Drug Administration in November 2021 for the treatment of advanced solid cancer patients with unresectable or metastatic microsatellites (MSI-H) or mismatched repair gene defects (dMMR).